Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL-TCM cells for advanced pancreatic cancer
NCT05438797Phase 1Unknown
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of TIL-TCM in pancreatic cancer (PC). Status: unknown.
02
Drugs
TIL-TCM
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05438797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438797.